drugset
drugset / Trial / NCT02933580

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants

NCT02933580 ↗

Phase 1 Completed 32 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of JNJ-56136379 in healthy Japanese adult participants following oral administration of single doses from 25 milligram (mg) up to 600 mg, in fasted conditions.

Timeline

Start
2016-10-12
Primary completion
2017-02-04
Completion
2017-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject bersacapavir Other / unclassified 25 mg Oral
Subject bersacapavir Other / unclassified 150 mg Oral
Subject bersacapavir Other / unclassified 300 mg Oral
Subject bersacapavir Other / unclassified 600 mg Oral

Indications

No indication recorded.